- Home
- INGR vs LEGN Comparison
INGR vs LEGN Comparison
Compare INGR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INGR | LEGN |
|---|---|---|
| Founded | 1906 | 2014 |
| Country | United States | United States |
| Employees | N/A | 3200 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 3.6B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INGR | LEGN |
|---|---|---|
| Price | $97.21 | $18.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $128.57 | $61.33 |
| AVG Volume (30 Days) | 538.3K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 15.14 | N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $7,219,000,000.00 | N/A |
| Revenue This Year | $3.86 | $42.68 |
| Revenue Next Year | $2.95 | $30.52 |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $94.44 | $16.24 |
| 52 Week High | $123.49 | $37.50 |
Technical Indicators
Market Signals| Indicator | INGR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.38 |
| Support Level | N/A | $17.81 |
| Resistance Level | N/A | $19.36 |
| Average True Range (ATR) | 0.00 | 0.77 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 34.49 |
Price Performance
Historical ComparisonAbout INGR Ingredion Incorporated
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.